Imagenebio Inc (IMA)

$4.90 +0.15 (3.20%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	52.22M
Revenue (ttm)	800,000.00
Net Income (ttm)	-45.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,668.75%
Debt to Equity Ratio	0.00

Volume	4,600
Avg Vol	38,456
Day's Range	N/A - N/A
Shares Out	10.65M
Stochastic %K	68%
Beta	0.55
Analysts	Sell
Price Target	$16.00

Company Profile

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, In...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 345 6265

Website: www.inmagenebio.com

Address:

12526 High Bluff Drive, Suite 345, San Diego, United States